DOVER, Del. and EPALINGES, Switzerland, Dec. 10, 2024 /PRNewswire/ — Pilatus Biosciences Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its leading molecule, PLT012, for treating liver and intrahepatic bile duct cancer…